Our Goal

arrows2cancer logo.jpg
Ruthenium-peptide conjugates: arrows for selectively targeting breast cancer

Arrows2cancer aims to contribute to the chemotherapy field through the development of an innovative and precise chemotherapeutic for triple negative breast cancer. In particular, Arrows2cancer aims to overcome the limitations of the current drugs in clinical use by developing smart drug delivery systems (SDDSs) of ruthenium selectively to primary tumors and metastases of triple negative breast cancer. The structure of these SDDSs focuses on the differences between cancerous and healthy cells to introduce functional groups sensitive to a variety of tumor environment stimuli to achieve an optimization of the therapeutic efficiency of the ruthenium drug through its controlled release and more efficient delivery to the target.

Acronym:

Arrows2cancer

Reference:

PTDC/QUI-QIN/0146/2020 

Duration:

March, 2021 - February, 2024

Principal Investigator:

Tânia Morais

Funding:

€ 249.9k